Quarterly ResultAug 6, 2026, 07:27 AM
Aclaris Therapeutics Q2 2026 Results; Clinical & Pipeline Updates
AI Summary
Aclaris Therapeutics reported a net loss of $21.5 million for the second quarter of 2026, an increase from $15.4 million in the prior year, with total revenue decreasing slightly to $1.6 million. The company provided positive full top-line results from its Phase 1a trial of ATI-052, validating its potency and potential for extended dosing. Aclaris reaffirmed timelines for upcoming Phase 1b and Phase 2 clinical data readouts in the second half of 2026 and plans to initiate Phase 2b programs for ATI-052 and modzatinib in Q4 2026. The company expects its cash, cash equivalents, and marketable securities of $170.6 million to fund operations through the end of 2028.
Key Highlights
- Net loss for Q2 2026 was $21.5 million, compared to $15.4 million for Q2 2025.
- Total revenue for Q2 2026 was $1.6 million, compared to $1.8 million for Q2 2025.
- Research and development expenses increased to $18.1 million in Q2 2026 from $11.4 million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $170.6 million as of June 30, 2026.
- Cash runway is expected to fund operations through the end of 2028.
- Positive full top-line results from Phase 1a trial of ATI-052 were provided.
- Timelines reaffirmed for top-line results from Phase 1b ATI-052 and Phase 2 Bosakitug trials in H2 2026.
- Planned initiation of Phase 2b programs for ATI-052 and modzatinib in Q4 2026.
Price Impact
More from ACRS